Glenmark Pharmaceuticals Inc., USA Launches Latanoprost Ophthalmic Solution, 0.005%

Mahwah, New Jersey, February 14, 2025 – Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK), has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) in the U.S. market. The product is bioequivalent and therapeutically equivalent to Xalatan® (0.005%) Ophthalmic Solution by Upjohn US 2 LLC.

Market Insights​

According to IQVIA™ sales data for the 12-month period ending December 2024, the total market for Xalatan® Ophthalmic Solution (0.005%) recorded annual sales of approximately $113.5 million.

Management Commentary​

Marc Kikuchi, President & Business Head, North America, stated:

“We are excited to announce the launch of our fourth ophthalmic product, Latanoprost Ophthalmic Solution, 0.005%, further strengthening our presence in the ophthalmic segment. This addition underscores our commitment to meeting market needs and providing quality solutions for our customers.”

Click to expand...

About Glenmark Pharmaceuticals Ltd.​

Glenmark is a research-led global pharmaceutical company with operations in over 80 countries and a focus on respiratory, dermatology, and oncology therapeutic segments. The company operates 11 world-class manufacturing facilities across four continents.

• Ranked among the Top 100 biopharmaceutical companies by Pharmaceutical Sales (2023).
• Placed in the Top 50 Generics and Biosimilar companies by sales (2024).
• Recognized for Greenhouse Gas (GHG) emission reduction targets by the Science Based Target initiative (SBTi).

Conclusion​

With this launch, Glenmark continues to expand its ophthalmic portfolio in the U.S., reinforcing its position in the generics and biosimilars market. The company's strategic focus on sustainability, innovation, and therapeutic diversification positions it for further growth.